key: cord-0846591-fqg4jil6
authors: Huh, H. J.; Kim, D.-M.; Chae, S. L.
title: Comparison and analysis of various complementary diagnosis methods for the current situation and problems of COVID-19 diagnosis
date: 2021-01-15
journal: nan
DOI: 10.1101/2021.01.14.21249620
sha: f5819ee74d092aabfb2a7e726a9cc2bb870115af
doc_id: 846591
cord_uid: fqg4jil6

We evaluated and compared the diagnostic performance of two types of serological diagnostic tests: enzyme-linked immunosorbent assay (ELISA) and immunochromatographic assay (ICA), and fluorescence immunoassay (FIA) for detection of SARS-CoV-2 antigen and antibody to diagnose COVID-19 infections. This study is aimed to analyze and compare the current status and problems of COVID-19 diagnosis and various alternative diagnostic methods that are viable. The enrolled subjects in our study population were tested with real-time polymerase chain reaction (RT-PCR). ELISA and immunochromatographic diagnostic kit were used to diagnose 362 positive and 3010 negative SARS-CoV-2 RT-PCR confirmed specimens, and antigen fluorescence immunoassay kit was used on 62 positive and 70 negative SARS-CoV-2 RT-PCR confirmed samples for diagnosis. As a result, categorizing by the patient symptom onset days, PCL COVID19 Total Ab EIA (ELISA) showed the sensitivity of 93.4% from 15 to 21 days, 94.2% from over 22 day, and the specificity of 99.97%. PCL COVID19 IgG/IgM Rapid Gold (ICA) had a sensitivity of 86.9%, 97.4%, and the specificity of 98.14% respectively. PCL COVID19 Ag Rapid FIA sensitivity was 93.8% from 0 to 7 days, 71.4% from 8 to 12 day and specificity was 98.57%. In conclusion, COVID-19 Ab ELISA and ICA, and COVID-19 Ag FIA are all complementary and applicable diagnostic methods to resolve the current problems of COVID-19 diagnosis.

over 22 days, and the specificity of 99.97%. PCL COVID19 IgG/IgM Rapid Gold (ICA) had a sensitivity of 86.9%, 23 97.4%, and the specificity of 98.14% respectively. PCL COVID19 Ag Rapid FIA sensitivity was 93.8% from 0 to 7 24 days, 71.4% from 8 to 12 days and specificity was 98.57%. In conclusion, COVID-19 Ab ELISA and ICA, and (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

With the first identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 in December 2019 from Wuhan, Hubei Province, China, coronavirus disease 2019 (COVID-19) 2 was soon after declared as a pandemic in March 2020 by World Health Organization (WHO) 1 . 3

The virus has not ceased to spread until now, resulting in tremendous public health challenges 4 across the world with over 61 million confirmed cases reported worldwide as of 30 November 5 2020 2, 3 . 6 COVID-19 diagnostic test samples are obtained from either a patient's blood or naso-7 oropharyngeal specimen. Molecular diagnostic tests, such as next generation sequencing or real-8 time polymerase chain reaction (RT-PCR), have been recommended to detect SARS-CoV-2 9 from the upper and lower respiratory tract swab samples for COVID-19 diagnosis 3-7 . However, 10 this method requires at least for 6 or more hours, to accurately process and determine the 11 COVID-19 infection of a patient 8 . In many cases where steep COVID-19 surges occur, 12 performing the molecular tests in a timely manner to close the gap between the high number of 13 patients and the limited number of laboratories has been a critical hinderance from devising of 14 efficient containment strategies for COVID-19 in many countries 9 . 15

In order to solve this problem, serological tests such as enzyme-linked immunosorbent assay 16 (ELISA) and immunochromatography have been developed to detect antibodies and antigens of 17 a virus. These methods now have become commercialized and can be easily accessed. This 18 allows to play a crucial role in overcoming the limitation of molecular diagnostic test as 19 alternative assays with the advantages such as ability to test large numbers of samples more 20 rapidly with less cost and perform an epidemiologic tracing in a short period of time 10, 11 . 21

Proper isolation and timely detection through a rapid diagnosis of COVID-19 is critical to 22 prevent the spreading of infection among the patients with recurrence of COVID-19, and to 23 decrease the associated prevalence and mortality rates due to unforeseen waves of the pandemic 8, 24 12 . Therefore, we evaluated and compared the diagnostic performance of two types of serological 25 diagnostic test ELISA and ICA for antibody detection and FIA for antigen detection of SARS-26

CoV-2. 27 28 29

30 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Study Design for serological test 1 A total of 50 patients diagnosed as COVID-19 positive were enrolled in this study. All enrolled 2 patients were confirmed to be infected with SARS-CoV-2 by the RT-PCR assays using 3 nasopharyngeal swabs. In the case of negative samples, 1072 residual samples were collected 4 from 1072 healthy people assessed by physical examination during early November of 2019, 5 before the pandemic of COVID-19, and the others collected from healthy donors without any 6 COVID-19 symptoms. A total of 3,372 human blood samples (serum), 362 COVID-19 positive 7 samples and 3,010 negative samples were used for this study. Regarding anticoagulant, 3372 8 serum samples were separated with gel without any anticoagulants. Positive and negative blood 9 samples for COVID-19 were used for the performance evaluation of the PCL COVID-19 Total 10

Ab EIA and the PCL COVID19 IgG/IgM Rapid Gold at DUMC under respective IRB approval 11 (DUIH 2020-03-025-003 and 110757-202003-HR-02-02). The performance evaluation was 12

conducted retrospectively by comparing the information including test results of the RT-PCR 13

In case of antigen test, we used nasopharyngeal swab samples in viral transport medium (VTM) 16 

Nasopharyngeal swabs were obtained from each patient for RT-PCR, which was performed 26 using the CFX96™ Real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA) with 27 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.14.21249620 doi: medRxiv preprint the Allplex™ 2019-nCoV Assay kit (Seegene Inc., Seoul, Korea) according to the 1 manufacturer's instructions. The assay is designed to detect RdRP and N genes specific for 2 SARS-CoV-2, and E gene for all of Sarbecovirus including SARS-CoV-2. 3 4

Lateral flow immunochromatographic assay (LFA) 6

To evaluate SARS-CoV-2 specific IgM and IgG antibodies, the LFA based rapid test (PCL 7 COVID19 IgG/IgM Rapid Gold) was performed following the manufacturer's instructions. Each 8 sample was tested by one test and readout (positive/negative) interpreted by two operators in 9 parallel. 10 11 Enzyme-linked immunosorbent assay (ELISA) 12

To evaluate total antibody response, the ELISA (PCL COVID19 Total Ab EIA test, PCL Inc., 13 Seoul, Korea) was performed following the manufacturer's instructions. All tests were performed which is used with the PCLOK EZ analyzer for the qualitative detection from SARS-CoV-2 in 20 nasopharyngeal specimens from individuals who are suspected of COVID-19 by their healthcare 21 provider, was performed following the manufacturer's instrument. 22

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 The sensitivity, specificity, positive predictive value (PPV), and negative predictive value 1 (NPV) were calculated, along with the 95% confidence interval (CI). A diagnostic value test of 2 the ELISA and rapid antibody method was performed with MedCalc software, version 19.5.1 3 (Mariakerke, Belgium). 4 5

Population of study sample 7

The overall contents of the study population are described ( (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.14.21249620 doi: medRxiv preprint IgG and IgM showed a similar positive rate until the 14 days period, but we noticed that the 1 positive rate of IgG began to gradually increase from 14 days and onwards (Figure1). 

We used PCL COVID19 Ag Rapid FIA to distinguish the patients who have been infected for 23 less than 14 days. With having all 62 samples already confirmed positive with RT-PCR test (0-24 12 days after symptom onset), the test result demonstrated that sensitivity was 93.8% (95% CI 25 82.80-98.69%) for 0-7 days period and 71.4% (95% CI 41.90-91.61%) for 8-12 days period 26 ( Figure 3) . We can conclude that the positive rate for antigen-based tests decreases as days go by 27 from the initial symptom onset period of a patient. Specificity was measured with a total of 70 28 RT-PCR confirmed negative samples, and only 1 out of 70 samples was false negative, resulting 29 in specificity of 98.57% (95% CI 92.30-99.96%) ( Table 2) . 30 31 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.14.21249620 doi: medRxiv preprint WHO announced that Chinese authorities had identified a novel type of coronavirus in January 7 6 2020 13 . RT-PCR, a nucleic acid amplification test (NAAT), was used as a COVID-19 diagnostic 7 test in many countries around the world, since the new coronavirus was identified4-7. However, 8

the RT-PCR test takes a lot of time to accurately diagnose the infection. To combat the current 9 COVID-19 pandemic, an efficient strategy for diagnosis of asymptomatic infections is required 10 because it is difficult to discern solely with a symptom-based RT-PCR screening. Asymptomatic 11

cases are reported to be 20 to 40% of the total incidence, or even higher, considering the 12 percentage of undetected COVID-19 infections 14, 15 Coronavirus is a single-stranded RNA virus that uses spike protein to enter host cells. 26

Coronavirus is composed of spike protein, membrane protein, envelope protein, and 27 nucleocapsid protein 4, 13 . In general, the diagnosis of COVID-19 infection is made using RT-28 PCR. While RT-PCR remains an effective microbial diagnostics technique, however, when used 29 alone in the areas of confirming COVID-19, there are some limitations or weaknesses, such as 30 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ;  https://doi.org/10.1101/2021.01.14.21249620 doi: medRxiv preprint the inability to differentiate virus viability and the development of indeterminate or false-1 negative results due to low target cell numbers in specimens 16 . To manage these problems, 2 different methods of diagnosis were required for suspected and supervised COVID-19 3

From the aforementioned reasons, complementary diagnosis is required in addition to the RT-5 PCR-based diagnostic method. Among them, COVID-19 Ab Enzyme-Linked Immunosorbent 6 Assay (ELISA), COVID-19 Ab Immunochromatographic rapid test, and COVID-19 Antigen 7

Fluorescent Immunoassay rapid test can be used. ELISA has proven its validity as a diagnostic 8 method for a long time since it was published by Peter Perlmann and Eva Engvall in 1971. The 9

fact that ELSIA can be implemented to a large-scale automatized equipment makes it a suitable 10 complementary diagnosis method regarding the current issue with the COVI-19 pandemic. 11

Immunochromatography was developed with the aim of detecting antigens in blood in the late 12 1960s and has been validated as a diagnostic method for various infections. The advantages 13 of immunochromatography are its simple test methods, significantly shorter time required to 14 prepare samples and reagents compared to other methods, and inexpensive equipment required 15 for making a diagnosis. Also, it can be applied in various environments both indoor and outdoor 16 settings. Immunochromatography is a suitable complementary diagnosis method for RT-PCR 17 test which has limitations such as operation time, operable environment, and number of samples 18 the test can diagnose at once. Lastly, the COVID-19 Nucleocapsid protein Antigen Fluorescent 19

Immunoassay has gone through major developmental breakthroughs over the years, and has 20 shown prominence in reagent simplification, simple analysis design, and high-sensitivity 21 detection. Fluorescent Immunoassay uses a fluorescent compound that absorbs light or energy of 22 a specific wavelength and emits light or energy at another wavelength. This fluorescent 23 compound offers an advantage of being able to check the results in a short time using a small 24 analyzer as a detection reagent. 25 PCL COVID19 Total Ab EIA (ELISA) showed the sensitivity of 93.4% from 15 to 21 days, 26 94.2% from over 22 day, and the specificity of 99.97%. PCL COVID19 IgG/IgM Rapid Gold 27 (ICA) had a sensitivity of 86.9%, 97.4%, and the specificity of 98.14% respectively. PCL 28 COVID19 Ag Rapid FIA sensitivity was 93.8% from 0 to 7 days, 71.4% from 8 to 12 day and 29 specificity was 98.57%. As a result, these diagnostic methods can be used as a complement to 30

Asymptomatic transmission during the COVID-19 pandemic 14 and implications for public health strategies

Prevalence of Asymptomatic SARS-CoV-2 Infection : A 16 Narrative Review

A Basic Guide to Real Time PCR in Microbial Diagnostics

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 the current diagnosis of COVID-19, before 14days of infection, SARS-CoV-2 antigen should be 1 tested and after 14days of infection, SARS-CoV-2 antibody should be tested. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

World Health Organization. Novel Coronavirus (2019-nCoV) situation report-1. 11All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.14.21249620 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.14.21249620 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101 /2021 doi: medRxiv preprint 1 Figure 2 . Levels of antibodies against SARS-CoV-2 in patient samples at different times 2 after symptom onset. SARS-CoV-2 antibody levels were measured for various periods in 16 3 patients with seroconversion, and the positive rate of antibodies measured within each week was 4 plotted on the graph. The X shape is less than S/CO 1, the point is S/CO 1 or more. The red 5 dotted line is S/CO 1(equal to cutoff) 6 7 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 15, 2021. ;  https://doi.org/10.1101/2021.01.14.21249620 doi: medRxiv preprint 1 Figure 4 . Antibody levels against SARS-CoV-2 according to the clinical characteristics of 2 the study population. Levels of antibodies against SARS-CoV-2 between patients with or 3 without underlying illness at different times after symptom onset. The X shape is less than S/CO 4 1, the point is S/CO 1 or more. The red dotted line is S/CO 1(equal to cutoff). 16 patients with 5 seroconversion(PCL COVID19 Total Ab EIA result) were picked up and studied. 6 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021